Recent Updates
Recently added Catalysts
SMMT Positive Sentiment

Summit Therapeutics to Host Corporate Update and Operational Progress Call on November 30, 2026

Key Takeaway: Summit Therapeutics Inc. will hold a corporate update and operational progress conference call on November 30, 2026, at 8:00 a.m. EST. Details for the call, including dial-in information, will be available on the company's Investor Relations website. Summit is dedicated to developing therapies that address serious unmet medical needs.

Market Sentiment Analysis

POSITIVE FACTORS

  • Summit Therapeutics will host a corporate update call.
  • The call is scheduled for November 30, 2026.
  • The company focuses on improving quality of life through therapies.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+14%
120-day peak, hindsight
Typical move
27.4%
average across 7 past catalysts
Cash runway
~11 mo
Medium dilution risk
Lead asset
Ivonescimab
Phase 3 · Non Small Cell Lung Cancer

Full Press Release Details

Conference Call to Be Held at 8:00 a.m. EST
Summit Therapeutics Inc. (Nasdaq: SMMT) will host a corporate update and operational progress conference call and webcast on Monday, November 30, 2026. The call is scheduled to take place at 8:00 a.m. EST.
The conference call and webcast details, including dial-in information and webcast link, will be posted on the Investor Relations section of Summit's website, www.smmttx.com. The archived webcast will be available through the company's website after the call has concluded.
About Summit Therapeutics
Summit Therapeutics Inc. is a biopharmaceutical oncology company focused on the discovery, development, and commercialization of patient-, physician-, caregiver- and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs.
Summit was founded in 2003 and its shares are listed on the Nasdaq Global Market (symbol "SMMT"). The company is headquartered in Miami, Florida, with additional offices in Palo Alto, California, Princeton, New Jersey, Dublin, Ireland, and Oxford, UK.
For more information, please visit https://www.smmttx.com and follow us on X @SMMT_TX.
Summit Forward-looking Statements
Any statements in this press release about the Company’s future expectations, plans and prospects, including but not limited to, statements about the clinical and preclinical development of the Company’s product candidates, entry into and actions related to the Company’s partnership with Akeso Inc. and other collaborations, the Company's anticipated spending and cash runway, the therapeutic potential of the Company’s product candidates, the potential commercialization of the Company’s product candidates, the timing of initiation, completion and availability of data from clinical trials, the potential submission of applications for marketing approvals, the expected timing of BLA submissions or FDA decisions, potential acquisitions, statements about the previously disclosed At-The-Market equity offering program (“ATM Program”), or the AstraZeneca private placement, the expected proceeds, uses thereof and possibility that the proceeds will not be sufficient to fund operations as long as anticipated, dilution to existing stockholders and potential adverse effects on the market price of the Company’s common stock, including from future sales by AstraZeneca, AstraZeneca’s ownership and contractual rights, including Third Party acquisition participation, registration rights and potential conflicts of interest, the Company’s reliance on third parties for the supply of third party products and other contributions to certain combination clinical trials, the Company’s estimates regarding stock-based compensation, and other statements containing the words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "would," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the Company’s ability to sell shares of our common stock under the ATM Program, the conditions affecting the capital markets, general economic, market, industry, or political conditions, including the effects of geopolitical developments, domestic and foreign trade policies, and monetary policies, the results of our evaluation of the underlying data in connection with the development and commercialization activities for ivonescimab, the outcome of discussions with regulatory authorities, including the Food and Drug Administration, the uncertainties inherent in the initiation of future clinical trials, availability and timing of data from ongoing and future clinical trials, the results of such trials, and their success, global public health crises, that may affect timing and status of our clinical trials and operations, whether preliminary results from a clinical trial will be predictive of the final results of that trial or whether results of early clinical trials or preclinical studies will be indicative of the results of later clinical trials, whether business development opportunities to expand the Company’s pipeline of drug candidates, including without limitation, through potential acquisitions of, and/or collaborations with, other entities occur, expectations for regulatory approvals, laws and regulations affecting government contracts and funding awards, availability of funding sufficient for the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements and other factors discussed in the "Risk Factors" and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of filings that the Company makes with the Securities and Exchange Commission. Summit defines a “positive study” as a clinical study with one or more prespecified primary endpoints in which one of those endpoints achieves a statistically significant benefit according to the protocol or statistical analysis plan. Any change to our ongoing trials could cause delays, affect our future expenses, and add uncertainty to our commercialization efforts, as well as to affect the likelihood of the successful completion of clinical development of ivonescimab. Accordingly, readers should not place undue reliance on forward-looking statements or information. In addition, any forward-looking statements included in this press release represent the Company’s views only as of the date of this release and should not be relied upon as representing the Company’s views as of any subsequent date. The Company specifically disclaims any obligation to update any forward-looking statements included in this press release.
Summit Therapeutics and the Summit Therapeutics logo are registered trademarks of Summit Therapeutics Inc. and/or its affiliates. Copyright 2026, Summit Therapeutics Inc. All Rights Reserved.

Frequently Asked Questions

When is the Summit Therapeutics conference call?

The conference call is scheduled for November 30, 2026, at 8:00 a.m. EST.

Where can I find the conference call details?

Details will be posted on the Investor Relations section of Summit's website.

What is the focus of Summit Therapeutics?

Summit focuses on developing therapies for serious unmet medical needs.

Will the conference call be available later?

Yes, an archived webcast will be available on the company's website after the call.

Last updated: Nov 19, 2026